Edesa Biotech Aktien im Umlauf
Was ist das Aktien im Umlauf von Edesa Biotech?
Aktien im Umlauf von Edesa Biotech, Inc. ist 18.154M
Was ist die Definition von Aktien im Umlauf?
Im Umlauf befindliche Aktien sind alle Aktien einer Gesellschaft oder eines finanziellen Vermögenswertes, die von Anlegern genehmigt, ausgegeben und gekauft wurden und von diesen gehalten werden.
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
Aktien im Umlauf von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Edesa Biotech
Was macht Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Unternehmen mit aktien im umlauf ähnlich Edesa Biotech
- Zhongchao hat Aktien im Umlauf von 18.103M
- New Destiny Mining hat Aktien im Umlauf von 18.106M
- Gulfport hat Aktien im Umlauf von 18.107M
- Aptose Biosciences Inc hat Aktien im Umlauf von 18.109M
- Vigil Health Solutions hat Aktien im Umlauf von 18.128M
- Orca hat Aktien im Umlauf von 18.151M
- Edesa Biotech hat Aktien im Umlauf von 18.154M
- New Home Inc hat Aktien im Umlauf von 18.161M
- Career Point hat Aktien im Umlauf von 18.163M
- Phio Pharmaceuticals hat Aktien im Umlauf von 18.164M
- Vasta Platform hat Aktien im Umlauf von 18.169M
- Cosmo Films hat Aktien im Umlauf von 18.173M
- V-Mart Retail hat Aktien im Umlauf von 18.174M